Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer (CHIP)

This study has been completed.
Sponsor:
Collaborator:
University Medical Centre Groningen
Information provided by (Responsible Party):
J.R. Kroep, Leiden University Medical Center
ClinicalTrials.gov Identifier:
NCT01639885
First received: April 16, 2012
Last updated: January 6, 2014
Last verified: January 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)